Malondialdehyde as an Indicator of Ischaemic Heart Disease

Afife İzbırak

Malondialdehyde as an Indicator of Ischaemic Heart Disease

Abstract

Lipids are the most involved class of molecules among the many targets of oxidative stress. Lipid oxidation producesa number of secondary products. The principal and most studied product of polyunsaturated fatty acid peroxidationis malondialdehyde MDA . Beside being a highly toxic molecule, malondialdehyde is also considered as a marker oflipid peroxidation. This study was intended to determine the lipid endoperoxide levels of some Turkish patients withischaemic heart disease findings at coroner angiography and verify whether malondialdehyde could be an indicatorof ischaemic heart disease. For this purpose lipid peroxide levels of the control and test groups were measured withspectrophotometric method which is based on the reaction between malondialdehyde and thiobarbituric acid. Statistical analysis of our results revealed a significant difference between the mean serum lipid peroxide levels of the patiens and the control group being 3.74±0.44 nmol/ml vs 2.72±0.53 nmol/ml respectively, and p=0.258. According tothese results we concluded that presence of MDA in serum at certain levels may predict the insurgence of vascularpathologies

Keywords

Oxidative stress,malondialdehyde,Lipid peroxidation,ischaemic heart disease

References

Jain, S.K., The accumulation of malondialde- hyde, a product of fatty acid peroxidation, can disturb amino phospholipid organization in the membrane bilayer of human eryhrocytes. J. Biol. Chem., 259, 3391-3394, 1984.
Palinski, W., Rosenfeld, M.E., Yla-Herttuala, S., Gurtner, G.C., Socher, S.S., Butler, S.W., Parthasarathy, S., Carew, T.E., and Steinberg, D., Low density lipoprotein undergoes oxida- tive modification in vivo. Proc. Natl. Acad. Sci. USA, 86, 1372-1376, 1989.
Wirtzum, J.L., and Steinberg, D., Role of oxi- dized low density lipoprotein in atherogenesis. J. Clin. Invest., 88, 1785-1792, 1991.
Berliner, J.A., Navab, M., Fogelman, A.M., Frank, J.S., Demer, L.L., Edwards, P.A., Wat- son, A.D., and Lusis, A.J., Atherosclerosis: basic meachanisms. Oxidation, inflammation, and genetics. Circulation, 91, 2488-2496
Holvoet, p., Collen, D., Oxidation of low density lipoproteins in the pathogenesis of atheroscle- rosis. Atherosclerosis, 137 Suppl. S33-S38, 1998.
Napoli, C., Quehenberger, O., De Nigris, F., Abete, P., Glass, C.K., Palinski, W., Mildly oxi- dized low density lipoprotein activates multiple apoptotic signaling pathways in human coro- nary cells. FASEB J. 14, 1996-2007, 2000.
Brand, K., Eisele, T., Kreusel, U., Page, M., Haas, H., Gerling, A., Kaltshmidt, C., et.al., Dysregulation of monocytic nuclear factor - kappa B by oxidized low-density lipoprotein. Ar- terioscler. Thromb. Vas. Biol., 17, 1901-1907, 1997.
Ohkawa, H., Ohishi, N.,and Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbi- turic acid reaction. Anal. Biochem., 95,351-358, 1979.

Knight, J. A., Pieper, R. K., and McClellan, L., Specificity of the thiobarbituric acid reaction: its use in studies of lipid peroxidation. Clin. Chem., 34, 2433-2438, 1988.
Arıcı, H., İstatistik, Meteksan Yayınları, Ankara, 1991.
İzbırak, A., Serum selenium levels in ischaemic heart disease. Hacettepe J. Biol. Chem. 35, 2, In press.
Korantzopoulos, P., Galaris, D., Papaioan- nides, D., Siogas, K., The possible role of ox- idative stress in heart failure and the potential role of antioxidant intervention. Med. Sci. Monit., 9(6), 140-145, 2003.
Amaki, T., Suzuki, T., Nakamura, F., Hayashi, D., Imal, Y., Morita, H., Fukino, K., et al. Circu- lating malondialdehyde modified LDL is a bio- chemical risk marker for coronary artery disease. Heart, 90, 1211-1213, 2004.
Holvoet, P., Kritchevsky, S.B., Tracy, R. P., et al. The metabolic syndrome, circulating oxi- dized LDL and risk of myocardial infarction in well-functioning elderly people in the health, aging and body composition cohort. Diabetes, 53, 1068-1073, 2004
Bird, R.P., and Draper, H.H., Comperative stud- ies on different methods of malondialdehyde determination. Methods Enzymol. 105, 299- 305, 1984.
Sim, A.S., Salonikas, C., Naidoo, D., and Wilcken, D.E., Improved method for plasma malondialdehyde measurement by high-per- formance liquid choromatography using methyl malondialdehyde as an internal standart. J. Choromatogr. B Analty. Tech. Biomed. Life Sci., 785, 337-344, 2003.
Boaz, M., Matas, Z., Biro, A., Katzir, Z., Green, M., and Fainaru, M. et al., Serum malondialde- hyde and prevalent cardiovascular disease in hemodialysis. Kidney Ins. 56, 1078-1083, 1999.
Boaz, M., Matas, Z., Biro, A., Katzir, Z., Green, M., and Fainaru, M. et al., Comparison of he- mostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am. J. Kidney Dis., 34, 438-444,1999.
Del Rio, D., Steward, A.J., and Pellegrini, N., A review of recent studies on malondialdehyde as toxic molecule and biological marker of ox- idative stress. Nut. Met. and Cardiovas. Dis- ease, 15 (4), 316-328, 2005.
Nand, N., Budhiraja, N., Singh, G.P., Sharma. M., and Aggarwal, H.K., Lipid peroxidation and vitamin E in ischaemic heart disease. J. Assoc. Physicians India, 45 (11), 839- 842, 1997.
Salonen, J.T., Salonen, R., Penttila, I., Herra- nen,J., et al. Serum fatty acids, apolipopro- teins, selenium and vitamin oxidants and the risk of death from coronary artery disease. Am. J. Cardiol., 56, 226-231, 1985.
Steinberg, D., and Wirtzum, J. L., Lipoproteins and atherogenesis. Jama, 264 (23), 3046- 3052, 1990.
Kharb, S., and Singh, G.P., Effect of smoking on lipid profile, lipid peroxidation and antioxi- dant status in normal subjects and in patients during and after acute myocardial infarction. Clin. Chim. Act., 302 (1-2), 213-219, 2000.
Herbacynka-Cedro, K., Kosiewicz-Wasek, B., Cedro, K., Wasek, W., et al., Supplementation with vitamins C and E suppresses leucocyte oxygene free radical production in patients with myocardial infarction. Eur. Heart J., 16 (8), 1044-1049, 1995.
Kumar, D., Lou, H., and Singal, P. K., Oxidative stress and apoptosis in heart dysfunction. Herz, 27, 662-668, 2002.
Hecker, M., and Ullrich, V., On the mechanism of prostacyclin and thromboxane A2 biosythe- sis. J. Biol. Chem., 264, 141-150, 1989.
Marnett, L. J., Lipid peroxidation-DNA damage by malondialdehyde. Mutat. Res., 424, 83-95
Vander Veen, L. A., Hashim, M. F., Shyr, Y., and Marnett, L. J., Induction of frameshift and base pair substitution mutations by the major DNA adduct of the endogeneous carcinogen malon- dialdehyde. Proc. Nat. Acad. Sci. USA, 100, 14247-14252, 2003.
Niedernhofer, L.J., Daniels, J. S., Rouzer, C. A., Greene, R. E., and Marnett, L.J., Malondi- aldehyde a product of lipid peroxidation is mu- tagenic in human cells. J. Biol. Chem., 278, 31426-31433, 2003.

Details

Primary Language

English

Subjects

-

Journal Section

-

Authors

Afife İzbırak This is me

Publication Date

April 1, 2007

Submission Date

-

Acceptance Date

-

Published in Issue

Year 2007 Volume: 35 Number: 2

IZ

https://izlik.org/JA33RN26MG

Cite

RIS / Bibtex

APA

İzbırak, A. (2007). Malondialdehyde as an Indicator of Ischaemic Heart Disease. Hacettepe Journal of Biology and Chemistry, 35(2), 77-81. https://izlik.org/JA33RN26MG

AMA

1.İzbırak A. Malondialdehyde as an Indicator of Ischaemic Heart Disease. HJBC. 2007;35(2):77-81. https://izlik.org/JA33RN26MG

Chicago

İzbırak, Afife. 2007. “Malondialdehyde As an Indicator of Ischaemic Heart Disease”. Hacettepe Journal of Biology and Chemistry 35 (2): 77-81. https://izlik.org/JA33RN26MG.

EndNote

İzbırak A (April 1, 2007) Malondialdehyde as an Indicator of Ischaemic Heart Disease. Hacettepe Journal of Biology and Chemistry 35 2 77–81.

IEEE

[1]A. İzbırak, “Malondialdehyde as an Indicator of Ischaemic Heart Disease”, HJBC, vol. 35, no. 2, pp. 77–81, Apr. 2007, [Online]. Available: https://izlik.org/JA33RN26MG

ISNAD

İzbırak, Afife. “Malondialdehyde As an Indicator of Ischaemic Heart Disease”. Hacettepe Journal of Biology and Chemistry 35/2 (April 1, 2007): 77-81. https://izlik.org/JA33RN26MG.

JAMA

1.İzbırak A. Malondialdehyde as an Indicator of Ischaemic Heart Disease. HJBC. 2007;35:77–81.

MLA

İzbırak, Afife. “Malondialdehyde As an Indicator of Ischaemic Heart Disease”. Hacettepe Journal of Biology and Chemistry, vol. 35, no. 2, Apr. 2007, pp. 77-81, https://izlik.org/JA33RN26MG.

Vancouver

1.Afife İzbırak. Malondialdehyde as an Indicator of Ischaemic Heart Disease. HJBC [Internet]. 2007 Apr. 1;35(2):77-81. Available from: https://izlik.org/JA33RN26MG